As such, CD70 expression has been reported on both primary and metastatic tumor resections in renal cell carcinoma, nasopharyngeal carcinoma, glioblastoma, melanoma, lung carcinoma, cervix carcinoma, breast carcinoma, ovarian carcinoma and mesothelioma and was associated with decreased survival [9, 82–86]. This evidence concerns the gene CD70 and ovarian carcinoma.